OBJECTIVE：To systematically review the effect of ticagrelor versus prasugrel on platelet reactivity， and provide evidence-based reference for clinical treatment. METHODS： Retrieved from PubMed， CJFD and Wanfang Database， randomized controlled trials （RCT） about the effect of ticagrelor versus prasugrel on platelet reactivity were collected. Meta-analysis was performed by using Rev Man software after data extract and quality evaluation by Cochrane 5.1.0. RESULTS： Totally 17 RCTs were enrolled， involving 2 757 patients. Results of Meta-analysis showed， regardless of Verity Now （VN） detection method [MD＝15.43， 95％CI（－0.39，31.25），P＝0.06] or vasodilator stimulus phosphoprotein （VASP） detection method [MD＝－3.04， 95％CI（－8.98，2.90）， P＝0.32]， ticagrelor and prasugrel had the same effects on platelet reactivity under loading dose， the differences were not statistically significant； regardless of VN detection method [MD＝－48.94， 95％CI（－58.04，－39.84），P＜0.001] or VASP detection method [MD＝－14.32， 95％CI（－20.45，－8.20）， P＜0.001]， the effects of ticagrelor were better than prasugrel on platelet reactivity under maintenance dose， the differences were statistically significant. CONCLUSIONS： At the loading dose， there was no difference between ticagrelor and prasugrel， but ticagrelor has more benefits than prasugrel under maintenance dose.